The company, founded in 2022, last year raised $52 million in a Series A funding round led by investors Eight Roads and 3E Bioventures.

Arnatar is developing ART4, an antisense oligonucleotide that ups the expression of its target protein to treat a rare ...

Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration ...

This study reveals that RNA silencing component Argonaute 2 (AGO2) loads small RNAs at endoplasmic reticulum–chloroplast membrane contact sites with the help of RNA helicase 3 (RH3), which also ...

A team of researchers from the Spanish National Research Council, an entity attached to the Spanish Ministry of Science, Innovation, and Universities, has made a significant advance in plant ...

The new technology incorporates novel compositions of inverted RNAi molecules that have shown a marked ability to co-silence mutated KRAS and over-expressed MYC. RNA interference (RNAi) is a ...

University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a "two-in-one" molecule that can simultaneously turn off two notoriously difficult-to-target cancer ...

A critical component in this process is the formation of R-loops—open DNA structures where RNA binds, signaling the system to initiate gene silencing. "The 'R' in R-loop stands for RNA.

HIV-1 elicits RNA silencing in human cells, but also contains a sequence that suppresses the process, researchers report in the May issue of Immunity. Coauthor Yamina Bennasser and her colleagues ...

In 1957, just four years after Francis Crick and other scientists solved the riddle of DNA’s structure—the now famous double ...

DNA’s chemical cousin, RNA, was the messenger that carries DNA instructions from the double helix in the cell’s nucleus to ...